☆ 4.6 Review

Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Related references

Note: Only part of the references are listed.
Editorial Material Cardiac & Cardiovascular Systems

Scientists Identify Molecular Alterations in Failing Hearts at Single-Cell Resolution

Tracy Hampton

CIRCULATION (2023)

Add to Collection
Article Cardiac & Cardiovascular Systems

Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

Rudolf A. de Boer et al.

Summary: This article discusses the pathogenesis, clinical presentation, and new medications and therapeutic approaches for genetic cardiomyopathies. With the use of contemporary research methods and tools, our understanding of cardiomyopathies has deepened, opening up new avenues for precision medicine.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection
Review Endocrinology & Metabolism

Current and future treatment approaches for Barth syndrome

Reid Thompson et al.

Summary: Barth Syndrome is a genetic disorder caused by pathogenic variants in the TAFAZZIN gene, which results in symptoms affecting the heart, neutrophils, growth, and skeletal muscles. Current treatment focuses on symptom management and clinical trials are exploring new treatments targeting the mitochondrial pathology of the disease. Future treatments may include enzyme and gene therapies to directly target the defective TAFAZZIN pathway.

JOURNAL OF INHERITED METABOLIC DISEASE (2022)

Add to Collection
Article Multidisciplinary Sciences

Changes in transcriptomic landscape in human end-stage heart failure with distinct etiology

Miaomiao Zhu et al.

Summary: This study discovered that HF is regulated by complex noncoding RNA networks, which vary depending on the etiology of HF. These networks include shared pathways and distinct pathways enriched in specific etiologies. Additionally, the identified HF biomarkers have significant clinical applications in HF staging and diagnosis.

ISCIENCE (2022)

Add to Collection
Review Cardiac & Cardiovascular Systems

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review

Jay M. Edelberg et al.

Summary: Hypertrophic cardiomyopathy is a complex heart disease with diverse clinical presentations. By studying the effects of mavacamten on cardiac myosin activity, we have developed a pathophysiological pathway model for hypertrophic cardiomyopathy, confirming the key role of excess sarcomeric activity.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2022)

Add to Collection
Review Endocrinology & Metabolism

Metabolic and Metabolomics Insights into Dilated Cardiomyopathy

Isaac Ampong

Summary: Metabolomics is a powerful discipline that can provide valuable insights into the phenotype of diseases like dilated cardiomyopathy (DCM). This review summarizes the current knowledge on metabolite-based biomarkers for predicting, diagnosing, and monitoring therapeutic interventions of DCM. The identified biomarkers include acylcarnitines, succinic acid, malate, methylhistidine, aspartate, methionine, and phenylalanine for diagnosing DCM; 1-pyrroline-2-carboxylate, norvaline, lysophosphatidylinositol (16:0/0:0), phosphatidylglycerol, fatty acid esters of hydroxy fatty acid, and phosphatidylcholine for differentiating DCM from ischemic cardiomyopathy; and acylcarnitines, isoleucine and linoleic acid, and tryptophan for monitoring treatment response to DCM. Dysregulation of branch-chain amino acid, glycolysis, tricarboxylic acid cycle, and triacylglycerol and pentose phosphate metabolism pathways were found to be associated with DCM. However, further research with larger sample sizes and validation in clinical settings is still needed.

ANNALS OF NUTRITION AND METABOLISM (2022)

Add to Collection
Article Cardiac & Cardiovascular Systems

Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy

Michael J. Previs et al.

Summary: This study identified metabolic reprogramming in human HCM hearts, characterized by deficits in nucleotide availability, reduced capacity for fatty acid oxidation, and increases in ketone bodies and branched chain amino acids. These findings have important therapeutic implications for the future design of metabolic modulators to treat HCM.

CIRCULATION-HEART FAILURE (2022)

Add to Collection
Review Cardiac & Cardiovascular Systems

Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects

Jason R. B. Dyck et al.

Summary: SGLT2 inhibitors have promising effects in treating heart failure patients. This review summarizes the cardiac effects of SGLT2i, including their impact on inflammation, oxidative stress, ion transport, and metabolism. These mechanisms play a crucial role in the development of heart failure.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2022)

Add to Collection
Article Pathology

HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma

Yuji Sekine et al.

Summary: In patients with malignant lymphoma, overexpression of HADHB is associated with poor prognosis. Silencing of HADHB gene and treatment with the FAO inhibitor ranolazine and ferroptosis inhibitor ferrosatin-1 can suppress cell proliferation and induce cell death in malignant lymphoma, providing a basis for the development of new therapeutic strategies.

PATHOLOGY (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Transcriptomal Insights of Heart Failure from Normality to Recovery

Mohammed Quttainah et al.

Summary: Current management of heart failure focuses on symptom progression and left ventricular dysfunction. This study investigated transcriptome changes in a chronic progressive heart failure model and identified potential genes involved in the progression of heart failure for future targeted therapies.

BIOMOLECULES (2022)

Add to Collection
Article Cardiac & Cardiovascular Systems

Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy

Isaac Perea-Gil et al.

Summary: This study established a phenotypic screening platform using DCM iPSC-CMs for therapeutic target discovery. It found that a combination of SMKIs ameliorated contractile and metabolic dysfunction in DCM iPSC-CMs through the ATF4-dependent serine biosynthesis pathway. These findings suggest that modulation of serine biosynthesis signaling may represent a novel genotype-agnostic therapeutic strategy for genetic DCM.

EUROPEAN HEART JOURNAL (2022)

Add to Collection
Article Cell Biology

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy

Zirui Qiu et al.

Summary: In this study, the cardiac fibrosis in ACM and its underlying mechanism were investigated using a CS-Dsg2(-/-) mouse model. It was found that activation of PPAR alpha alleviates the cardiac fibrosis in ACM.

CELLS (2022)

Add to Collection
Article Multidisciplinary Sciences

Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy

Mark Chaffin et al.

Summary: The study identified extensive molecular alterations in failing hearts through single-nucleus RNA sequencing, including changes in transcriptional profiles and the presence of a unique population of activated fibroblasts that are almost absent from non-failing samples. The findings provide new insights into the transcriptional diversity of the human heart in health and disease, as well as potential therapeutic targets and biomarkers for heart failure.

NATURE (2022)

Add to Collection
Article Medicine, General & Internal

Oxidative Stress Markers in Hypertrophic Cardiomyopathy

Bozena Szygula-Jurkiewicz et al.

Summary: This study revealed that secondary alterations in the heart related to oxidative stress are present in patients with hypertrophic cardiomyopathy (HCM), and the oxidative stress index (OSI) is an excellent marker for identifying HCM patients.

MEDICINA-LITHUANIA (2022)

Add to Collection
Review Cardiac & Cardiovascular Systems

The Role of Metabolism in Heart Failure and Regeneration

Jiyoung Bae et al.

Summary: The regenerative potential of the mammalian heart is lost by the first week of postnatal development due to a metabolic shift from glycolysis to fatty acid oxidation. Understanding the mechanisms that regulate cardiac metabolism is key to developing metabolic interventions for the treatment of heart diseases.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection
Review Cardiac & Cardiovascular Systems

Epidemiology of the inherited cardiomyopathies

William J. McKenna et al.

Summary: Estimates of the incidence and prevalence of inherited cardiomyopathies are challenging due to incomplete and late-onset disease expression, highly variable penetrance within families, and overlapping phenotypes. Current global estimates for hypertrophic, dilated, and arrhythmogenic cardiomyopathies may be conservative.

NATURE REVIEWS CARDIOLOGY (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy

Maike Schuldt et al.

Summary: The study found that microtubules and their detyrosination play an important role in the pathomechanism of patients with HCMSMP, potentially serving as a target for improving cardiac function. However, the beneficial effect may be limited in patients with HCMSMN.

CIRCULATION-HEART FAILURE (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy

Sara Ranjbarvaziri et al.

Summary: The study found that metabolic signaling disruption and mitochondrial dysfunction are common pathogenic mechanisms in patients with HCM, highlighting potential new drug targets for mitigating the disease by improving metabolic function and reducing mitochondrial injury.

CIRCULATION (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy

Tim R. Eijgenraam et al.

Summary: The p.(Arg14del) pathogenic variant of the PLN gene is a common cause of cardiomyopathy and heart failure. This study on PLN-R14(Delta/Delta) mice identified early manifestations of cardiomyopathy including myocardial fibrosis, ventricular dilatation, and altered protein homeostasis pathways. Transcriptomics and proteomics revealed differential regulation of processes involved in remodeling, inflammation, and metabolic dysfunction.

CIRCULATION-HEART FAILURE (2021)

Add to Collection
Review Endocrinology & Metabolism

Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease

Carlos R. Ferreira et al.

Summary: Inherited metabolic diseases make up a significant portion of pediatric cardiomyopathy cases, with a high mortality rate. These diseases can also lead to other cardiovascular complications such as arrhythmias and vasculopathies. The authors compiled a list of metabolic diseases associated with cardiovascular issues in order to aid in clinical and metabolic differential diagnoses.

MOLECULAR GENETICS AND METABOLISM (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Characteristics of Blood Metabolic Profile in Coronary Heart Disease, Dilated Cardiomyopathy and Valvular Heart Disease Induced Heart Failure

Chang Liu et al.

Summary: This study identified significant metabolic differences in patients with CHD-, VHD-, and DCM-induced heart failure. Certain metabolites were found to be related to the occurrence and differentiation of HF subtypes. Circulating amino acids and long-chain acylcarnitine levels were closely associated with heart failure progression. Monitoring these metabolic alterations may aid in early differentiation and offer new diagnostic or therapeutic targets.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection
Review Cardiac & Cardiovascular Systems

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review

Azita H. Talasaz et al.

Summary: COVID-19 is associated with systemic inflammation and endothelial activation, and lipid-modulating agents may have potential benefits in treating patients. Several randomized controlled trials are ongoing or completed to investigate the effects of these agents, but only preliminary results from a few trials are currently available.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy

Jan Haas et al.

Summary: This study identified a new set of metabolomic biomarkers for heart failure (HF) through a multi-OMICS approach, revealing underlying biological cascades that potentially represent suitable intervention targets.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Evidence-Based Assessment of Genes in Dilated Cardiomyopathy

Elizabeth Jordan et al.

Summary: A systematic curation of 51 genes related to DCM revealed that 19 genes have high evidence (12 definitive/strong, 7 moderate), but these genes only explain a minority of cases, leaving the remainder of DCM genetic architecture incompletely addressed.

CIRCULATION (2021)

Add to Collection
Article Medicine, Research & Experimental

Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation

Friederike Cuello et al.

Summary: The PLN p.Arg14del mutation causes dilated cardiomyopathy with impairment of the ER/mitochondria compartment, leading to prolonged Ca2+ transient decay time and irregular beating pattern. Interventions with Ca2+-binding proteins improved the disease phenotype, suggesting impaired local Ca2+ cycling as an important disease culprit.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection
Article Oncology

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations

J. Pei et al.

Summary: Through integrating histone acetylome, transcriptome, and proteome profiles, we identified major effector genes and protein networks driving pathological changes in HCM with mutated MYBPC3. Our work identifies 38 highly affected protein-coding genes as potential plasma HCM biomarkers and 9 TFs as potential upstream regulators of these pathomechanisms that may serve as possible therapeutic targets.

CLINICAL EPIGENETICS (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Metabolic Signature of Arrhythmogenic Cardiomyopathy

Chiara Volani et al.

Summary: ACM is a genetic-based cardiac disease characterized by severe ventricular arrhythmias and substitution of myocardium with fibro-fatty tissue. Studies have shown dysregulated metabolic status in ACM patients, with altered metabolomes compared to healthy controls, including pathways such as tryptophan metabolism, arginine and proline metabolism, and beta oxidation of fatty acids. This indicates signs of endothelium damage, impaired nitric oxide, fat, and energy metabolism in ACM patients.

METABOLITES (2021)

Add to Collection
Article Endocrinology & Metabolism

Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy

Jin Yoo et al.

Summary: The study demonstrates that fenofibrate can promote intracellular lipid clearance by activating TFEB and TFE3, leading to reduced hepatic fat accumulation. The lysosomal calcium signaling pathway appears to be critical in this process, suggesting a potential therapeutic target for NAFLD and cardiometabolic diseases.

METABOLISM-CLINICAL AND EXPERIMENTAL (2021)

Add to Collection
Review Cardiac & Cardiovascular Systems

PPAR control of metabolism and cardiovascular functions

David Montaigne et al.

Summary: Novel PPAR agonists offer new opportunities for managing metabolic and cardiovascular diseases by regulating gene expression, lipid metabolism, insulin sensitivity, glucose metabolism, and cardiovascular health. Activation of PPARs by specific ligands can have antiatherogenic, anti-inflammatory, and metabolic benefits, making them important therapeutic targets in the treatment of various diseases.

NATURE REVIEWS CARDIOLOGY (2021)

Add to Collection
Article Multidisciplinary Sciences

Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state

Alison Schroer Vander Roest et al.

Summary: The study found that the P710R mutation results in a shorter step size of the myosin motor, decreased load sensitivity, and destabilization of the super relaxed state, which increases force generation. Through CRISPR editing, cardiac myocytes with the P710R mutation were able to produce more force, leading to hypertrophy and cytoskeletal remodeling.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection
Article Cardiac & Cardiovascular Systems

Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy

Job A. J Verdonschot et al.

JOURNAL OF CARDIAC FAILURE (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis

Julia Ritterhoff et al.

CIRCULATION RESEARCH (2020)

Add to Collection
Article Medicine, Research & Experimental

Metabolic effects of bezafibrate in mitochondrial disease

Hannah Steele et al.

EMBO MOLECULAR MEDICINE (2020)

Add to Collection
Review Chemistry, Medicinal

Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)

Ichiro Takada et al.

EXPERT OPINION ON THERAPEUTIC PATENTS (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy

Charlotte L. Hall et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Inherited Metabolic Diseases and Cardiac Pathology in Adults: Diagnosis and Prevalence in a CardioMetabo Study

Marina Brailova et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection
Review Cell Biology

PPAR-Mediated Toxicology and Applied Pharmacology

Yue Xi et al.

CELLS (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure

Senthil Selvaraj et al.

CIRCULATION (2020)

Add to Collection
Editorial Material Cardiac & Cardiovascular Systems

Regression of left ventricular hypertrophy with SGLT2 inhibitors

Francesco Paneni et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection
Review Endocrinology & Metabolism

Clinical manifestations and management of fatty acid oxidation disorders

J. Lawrence Merritt et al.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)

Add to Collection
Article Medicine, General & Internal

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto et al.

LANCET (2020)

Add to Collection
Article Genetics & Heredity

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency

Tomonori Suyama et al.

MOLECULAR GENETICS AND METABOLISM REPORTS (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Plasma Metabolomic Profiles Differentiate Patients With Dilated Cardiomyopathy and Ischemic Cardiomyopathy

Junhan Zhao et al.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)

Add to Collection
Review Chemistry, Medicinal

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Na Li et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure

Golam M. Uddin et al.

CARDIOVASCULAR DIABETOLOGY (2019)

Add to Collection
Article Gastroenterology & Hepatology

Additional fibrate treatment in UDCA-refractory PBC patients

Sung Won Chung et al.

LIVER INTERNATIONAL (2019)

Add to Collection
Review Cardiac & Cardiovascular Systems

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure

Diem H. Tran et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)

Add to Collection
Article Cardiac & Cardiovascular Systems

Genetic relevance and determinants of mitral leaflet size in hypertrophic cardiomyopathy

Hyemoon Chung et al.

CARDIOVASCULAR ULTRASOUND (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

Hong Sheng Cheng et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection
Review Genetics & Heredity

Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency

Kenji Yamada et al.

JOURNAL OF HUMAN GENETICS (2019)

Add to Collection
Article Neurosciences

Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament

Thomas Kampourakis et al.

JOURNAL OF PHYSIOLOGY-LONDON (2018)

Add to Collection
Article Cardiac & Cardiovascular Systems

Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Jolanda van der Velden et al.

CARDIOVASCULAR RESEARCH (2018)

Add to Collection
Article Cardiac & Cardiovascular Systems

Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-termlife-threatening arrhythmias

Job A. J. Verdonschot et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Dilated cardiomyopathy myosin mutants have reduced force-generating capacity

Zoltan Ujfalusi et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2018)

Add to Collection
Article Cell Biology

Serine Availability Influences Mitochondrial Dynamics and Function through Lipid Metabolism

Xia Gao et al.

CELL REPORTS (2018)

Add to Collection
Article Cell Biology

Targeting Peroxisome Proliferator Activated Receptor α (PPAR α) for the Prevention of Mitochondrial Impairment and Hypertrophy in Cardiomyocytes

Dipak Kar et al.

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)

Add to Collection
Review Biochemistry & Molecular Biology

The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

Fan Hong et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases

Zaza Khuchua et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection
Article Clinical Neurology

Neutral lipid storage disease with myopathy and dropped head syndrome. Report of a new variant susceptible of treatment with late diagnosis

Mary A. Garcia et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2018)

Add to Collection
Review Cardiac & Cardiovascular Systems

Loss of Metabolic Flexibility in the Failing Heart

Qutuba G. Karwi et al.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2018)

Add to Collection
Article Cardiac & Cardiovascular Systems

Dilated Cardiomyopathy Genetic Determinants and Mechanisms

Elizabeth M. McNally et al.

CIRCULATION RESEARCH (2017)

Add to Collection
Article Cardiac & Cardiovascular Systems

Hypertrophic Cardiomyopathy Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy

Ali J. Marian et al.

CIRCULATION RESEARCH (2017)

Add to Collection
Article Cell Biology

Peroxisome Proliferator-Activated Receptor alpha Reduces Endothelin-1-Caused Cardiomyocyte Hypertrophy by Inhibiting Nuclear Factor-kappa B and Adiponectin

Hsu-Lung Jen et al.

MEDIATORS OF INFLAMMATION (2016)

Add to Collection
Article Endocrinology & Metabolism

A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy

James A. West et al.

METABOLOMICS (2016)

Add to Collection
Article Medicine, Research & Experimental

Molecular profiling of dilated cardiomyopathy that progresses to heart failure

Michael A. Burke et al.

JCI INSIGHT (2016)

Add to Collection
Article Cardiac & Cardiovascular Systems

N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy

Tanganyika Wilder et al.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)

Add to Collection
Article Medicine, Research & Experimental

Effects of ERK1/2/PPARα/SCAD signal pathways on cardiomyocyte hypertrophy induced by insulin-like growth factor 1 and phenylephrine

Qiuju Huang et al.

LIFE SCIENCES (2015)

Add to Collection
Article Medicine, Research & Experimental

KLF15 and PPAR alpha Cooperate to Regulate Cardiomyocyte Lipid Gene Expression and Oxidation

Domenick A. Prosdocimo et al.

PPAR RESEARCH (2015)

Add to Collection
Article Cardiac & Cardiovascular Systems

Inherited Cardiomyopathies

Jeffrey A. Towbin

CIRCULATION JOURNAL (2014)

Add to Collection
Article Medicine, Research & Experimental

Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy

Jason A. Magida et al.

EMBO MOLECULAR MEDICINE (2014)

Add to Collection
Article Biochemistry & Molecular Biology

Kruppel-like Factor 15 Is a Critical Regulator of Cardiac Lipid Metabolism

Domenick A. Prosdocimo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

Add to Collection
Article Clinical Neurology

Bezafibrate in skeletal muscle fatty acid oxidation disorders A randomized clinical trial

Mette Cathrine Orngreen et al.

NEUROLOGY (2014)

Add to Collection
Review Nutrition & Dietetics

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review

Bogna Grygiel-Gorniak

NUTRITION JOURNAL (2014)

Add to Collection
Article Endocrinology & Metabolism

Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling

Rebecca C. Schugar et al.

MOLECULAR METABOLISM (2014)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

Imaging of Myocardial Oxidative Metabolism in Heart Failure

Masanao Naya et al.

CURRENT CARDIOVASCULAR IMAGING REPORTS (2014)

Add to Collection
Review Cardiac & Cardiovascular Systems

Genetic Cardiomyopathies Causing Heart Failure

Thomas J. Cahill et al.

CIRCULATION RESEARCH (2013)

Add to Collection
Article Cardiac & Cardiovascular Systems

Impairment of Subendocardial Perfusion Reserve and Oxidative Metabolism in Nonischemic Dilated Cardiomyopathy

Susan P. Bell et al.

JOURNAL OF CARDIAC FAILURE (2013)

Add to Collection
Review Cardiac & Cardiovascular Systems

Glucose metabolism and cardiac hypertrophy

Stephen C. Kolwicz et al.

CARDIOVASCULAR RESEARCH (2011)

Add to Collection
Review Medicine, General & Internal

MECHANISMS OF DISEASE Inherited Cardiomyopathies

Hugh Watkins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection
Article Cardiac & Cardiovascular Systems

Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy

Khalid Abozguia et al.

CIRCULATION (2010)

Add to Collection
Article Pharmacology & Pharmacy

Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 Deficiency

J. P. Bonnefont et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)

Add to Collection
Article Endocrinology & Metabolism

LMNA Mutations, Skeletal Muscle Lipid Metabolism, and Insulin Resistance

Michael Boschmann et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)

Add to Collection
Review Biochemistry & Molecular Biology

Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism

Paul P. Van Veldhoven

JOURNAL OF LIPID RESEARCH (2010)

Add to Collection
Review Physiology

Myocardial Fatty Acid Metabolism in Health and Disease

Gary D. Lopaschuk et al.

PHYSIOLOGICAL REVIEWS (2010)

Add to Collection
Article Cardiac & Cardiovascular Systems

Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms

Raffaella Lombardi et al.

CIRCULATION (2009)

Add to Collection
Article Cell & Tissue Engineering

Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism

Fatemeh Sharifpanah et al.

STEM CELLS (2008)

Add to Collection
Article Cardiac & Cardiovascular Systems

Dilated and hypertrophic cardiomyopathy mutations in troponin and α-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments

Paul Robinson et al.

CIRCULATION RESEARCH (2007)

Add to Collection
Review Biochemistry & Molecular Biology

PPARs and molecular mechanisms of transrepression

Mercedes Ricote et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)

Add to Collection
Article Cardiac & Cardiovascular Systems

Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the α-tropomyosin gene:: A positron emission tomography study

Helena Tuunanen et al.

JOURNAL OF NUCLEAR CARDIOLOGY (2007)

Add to Collection
Article Cardiac & Cardiovascular Systems

Cardiac PPARα expression in patients with dilated cardiomyopathy

Michael Schupp et al.

EUROPEAN JOURNAL OF HEART FAILURE (2006)

Add to Collection
Article Cardiac & Cardiovascular Systems

Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation

AJ Marian et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)

Add to Collection
Article Cardiac & Cardiovascular Systems

Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy

JG Crilley et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)

Add to Collection
Review Medicine, Research & Experimental

Heart metabolic disturbances in cardiovascular diseases

K Carvajal et al.

ARCHIVES OF MEDICAL RESEARCH (2003)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.